Tradename | Company | Number | Date | Products |
---|---|---|---|---|
FYARRO | Aadi Bioscience | N-213312 RX | 2021-11-22 | 1 products, RLD, RS |
HYFTOR | Nobelpharma | N-213478 RX | 2022-03-22 | 1 products, RLD, RS |
RAPAMUNE | CV Sciences | N-021083 RX | 1999-09-15 | 1 products, RLD, RS |
RAPAMUNE | CV Sciences | N-021110 RX | 2000-08-25 | 3 products, RLD |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
perivascular epithelioid cell neoplasms | — | D054973 | — |
Expiration | Code | ||
---|---|---|---|
SIROLIMUS, HYFTOR, NOBELPHARMA | |||
2029-03-22 | ODE-391 | ||
2025-03-22 | NP | ||
SIROLIMUS, FYARRO, AADI | |||
2028-11-22 | ODE-386 | ||
2024-11-22 | NP |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neoplasms | D009369 | — | C80 | 2 | 3 | — | — | — | 5 |
Recurrence | D012008 | — | — | — | 2 | — | — | — | 2 |
Perivascular epithelioid cell neoplasms | D054973 | — | — | — | 1 | — | — | 1 | 2 |
Neuroendocrine tumors | D018358 | EFO_1001901 | D3A.8 | — | 2 | — | — | — | 2 |
Glioblastoma | D005909 | EFO_0000515 | — | — | 1 | — | — | — | 1 |
Glioma | D005910 | EFO_0000520 | — | — | 1 | — | — | — | 1 |
Colorectal neoplasms | D015179 | — | — | 1 | 1 | — | — | — | 1 |
Syndrome | D013577 | — | — | — | 1 | — | — | — | 1 |
Leigh disease | D007888 | Orphanet_506 | G31.82 | — | 1 | — | — | — | 1 |
Urinary bladder neoplasms | D001749 | — | C67 | 1 | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hypertension | D006973 | EFO_0000537 | I10 | 1 | — | — | — | — | 1 |
Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | 1 | — | — | — | — | 1 |
Pulmonary arterial hypertension | D000081029 | — | — | 1 | — | — | — | — | 1 |
Non-small-cell lung carcinoma | D002289 | — | — | 1 | — | — | — | — | 1 |
Epilepsy | D004827 | EFO_0000474 | G40.9 | 1 | — | — | — | — | 1 |
Drug resistant epilepsy | D000069279 | — | — | 1 | — | — | — | — | 1 |
Multiple myeloma | D009101 | — | C90.0 | 1 | — | — | — | — | 1 |
Plasma cell neoplasms | D054219 | — | — | 1 | — | — | — | — | 1 |
Drug common name | Sirolimus |
INN | sirolimus |
Description | Sirolimus is a macrolide lactam isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent. It has a role as an immunosuppressive agent, an antineoplastic agent, an antibacterial drug, a mTOR inhibitor, a bacterial metabolite, an anticoronaviral agent and a geroprotector. It is a cyclic acetal, a cyclic ketone, an ether, a secondary alcohol, an organic heterotricyclic compound, an antibiotic antifungal drug and a macrolide lactam. |
Classification | Small molecule |
Drug class | immunosuppressives |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C |
PDB | — |
CAS-ID | 53123-88-9 |
RxCUI | — |
ChEMBL ID | CHEMBL413 |
ChEBI ID | 9168 |
PubChem CID | 5284616 |
DrugBank | DB00877 |
UNII ID | W36ZG6FT64 (ChemIDplus, GSRS) |